Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Reports Positive Phase 2 Results of BMND08 for Depression in Alzheimer’s Disease
Details : BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is an oral formulation of a natural psychedelic called 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for the potential treatment of depression and anxiety in Alzheimer’s disease.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 28, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triptax
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triptax could be used as an API to treat depression, specifically Treatment-Resistant Depression, MDD in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat current depressive episodes...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Triptax
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trial is designed with fixed ascending two-dose, concentration-response study, allowing BMND01 (N,N-dimethyltryptamine) to be rapidly delivered directly into the systemic circulation in approximately 10 minutes, bypassing first-pass metabolism.
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The effects of intramuscular BMND01 (N, N-dimethyltryptamine) last for about one hour, while the inhaled formulation is expected to shorten these effects to a timeframe between ten to fifteen minutes for treatment-resistant depression.
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Labs Opens a New Clinical Psychedelic Research Facility
Details : BMND02 (n n-dimethyltryptamine), a serotonin 2A receptor agonist, for treatment-resistant depression under the new model of psychiatric intervention with DMT in conjunction with traditional psychological approaches.
Product Name : BMND02
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 (5-Methoxy-N,N-dimethyltryptamine) novel drug candidate which may allow us to address a new line of development to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase I/IIa clinical trial on Biomind's first innovative formulation of N,N-Dimethyltryptamine (“DMT”) is evaluating the safety, pharmacokinetics, behavioral and brain effects of BMND01, for inhaled administration.
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND01 candidate, a novel liquid inhaled formulation of N,N-Dimethyltryptamine (“DMT”) for Treatment-Resistant Depression, possible to scale-up treatments without the need to train a whole new generation of mental health professionals.
Product Name : BMND01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable